drugset / Trial / NCT00683436

Efficacy and Safety Study of Adipiplon, Placebo and an Active Control in Primary Insomniacs

NCT00683436

Phase 2 Terminated 84 enrolled Neurogen Corporation
RandomizedCrossoverTriple-blindTreatment

Summary

This will be a multi-center, randomized, blinded, comparative, placebo-controlled, 4 arm crossover study in patients with primary insomnia.

Timeline

Start
2008-05
Primary completion
2008-10
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Adipiplon Small molecule 6 mg
Subject Adipiplon Small molecule 9 mg
Subject Zolpidem Small molecule 12.5 mg

Indications